Christopher Lambert
Family · Monrovia, INNPI 1063801983
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 75.7% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2022 at $11,389 and has fallen 73.9% since, to $2,973 in 2025. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 553 payments — averaging $63.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$27K
- AstraZeneca$3K
- Lilly USA, LLC$859
- Amgen$556
- Novartis$429
- Novo Nordisk$384
- plus $4K from 37 others
What the payments were for
- Consulting fees$6,20018%
- Speaking & faculty fees$13,30038%
- Travel & lodging$4,02211%
- Food & beverage$11,54333%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,153 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 56 | $91,451 |
| MounjaroTirzepatide | 52 | $81,821 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $72,882 |
| TrulicityDulaglutide | 42 | $71,678 |
| OzempicSemaglutide | 56 | $59,861 |
| FarxigaDapagliflozin Propanediol | 49 | $46,144 |
| EliquisApixaban | 28 | $35,512 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $34,933 |
| XareltoRivaroxaban | 21 | $31,050 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $27,819 |
| UbrelvyUbrogepant | 16 | $21,730 |
| TradjentaLinagliptin | 13 | $19,098 |
| LinzessLinaclotide | 18 | $18,784 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $17,858 |
| VascepaIcosapent Ethyl | 24 | $16,701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $859 | $153,49994 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $139 | $145,48291 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $377 | $96,79680 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,801 | $73,96376 claims |
| Novo NordiskOzempic | $384 | $59,86156 claims |
| AbbVieUbrelvy, Linzess, Synthroid | $26,619 | $41,62550 claims |
| PfizerEliquis | $174 | $35,51228 claims |
| MerckJanuvia | $193 | $13,05116 claims |
| NovartisEntresto | $429 | $7,83112 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $112 | $7,74414 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $33 | $1,373156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Monrovia
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.